Galmed Pharmaceuticals Competitors

Galmed Pharmaceuticals (NASDAQ:GLMD) and Wave Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Risk and Volatility

Galmed Pharmaceuticals has a beta of 2.3, meaning that its stock price is 130% more volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Galmed Pharmaceuticals and Wave Life Sciences, as provided by MarketBeat.com.

Galmed Pharmaceuticals currently has a consensus price target of $18.1429, suggesting a potential upside of 490.97%. Wave Life Sciences has a consensus price target of $11.80, suggesting a potential upside of 88.20%. Given Galmed Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Galmed Pharmaceuticals is more favorable than Wave Life Sciences.

Insider and Institutional Ownership

31.5% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 80.7% of Wave Life Sciences shares are owned by institutional investors. 38.2% of Wave Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Galmed Pharmaceuticals and Wave Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

Galmed Pharmaceuticals has higher earnings, but lower revenue than Wave Life Sciences. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Wave Life Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Galmed Pharmaceuticals and Wave Life Sciences' net margins, return on equity and return on assets.

Summary

Galmed Pharmaceuticals beats Wave Life Sciences on 10 of the 14 factors compared between the two stocks.

ProQR Therapeutics (NASDAQ:PRQR) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.

Institutional & Insider Ownership

55.9% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 31.5% of Galmed Pharmaceuticals shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and price targets for ProQR Therapeutics and Galmed Pharmaceuticals, as reported by MarketBeat.

ProQR Therapeutics currently has a consensus price target of $32.6667, indicating a potential upside of 444.44%. Galmed Pharmaceuticals has a consensus price target of $18.1429, indicating a potential upside of 490.97%. Given Galmed Pharmaceuticals' higher probable upside, analysts plainly believe Galmed Pharmaceuticals is more favorable than ProQR Therapeutics.

Earnings & Valuation

This table compares ProQR Therapeutics and Galmed Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Galmed Pharmaceuticals has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

ProQR Therapeutics has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 2.3, indicating that its stock price is 130% more volatile than the S&P 500.

Profitability

This table compares ProQR Therapeutics and Galmed Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Galmed Pharmaceuticals beats ProQR Therapeutics on 8 of the 10 factors compared between the two stocks.

Immunic (NASDAQ:IMUX) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, profitability, risk and earnings.

Risk and Volatility

Immunic has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 2.3, indicating that its share price is 130% more volatile than the S&P 500.

Earnings & Valuation

This table compares Immunic and Galmed Pharmaceuticals' top-line revenue, earnings per share and valuation.

Galmed Pharmaceuticals has higher revenue and earnings than Immunic. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Immunic and Galmed Pharmaceuticals, as reported by MarketBeat.

Immunic currently has a consensus price target of $59.5556, indicating a potential upside of 319.11%. Galmed Pharmaceuticals has a consensus price target of $18.1429, indicating a potential upside of 490.97%. Given Galmed Pharmaceuticals' higher possible upside, analysts plainly believe Galmed Pharmaceuticals is more favorable than Immunic.

Profitability

This table compares Immunic and Galmed Pharmaceuticals' net margins, return on equity and return on assets.

Insider & Institutional Ownership

41.3% of Immunic shares are owned by institutional investors. Comparatively, 31.5% of Galmed Pharmaceuticals shares are owned by institutional investors. 12.1% of Immunic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Galmed Pharmaceuticals beats Immunic on 8 of the 12 factors compared between the two stocks.

Trevena (NASDAQ:TRVN) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Volatility and Risk

Trevena has a beta of 2.59, suggesting that its stock price is 159% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 2.3, suggesting that its stock price is 130% more volatile than the S&P 500.

Earnings & Valuation

This table compares Trevena and Galmed Pharmaceuticals' revenue, earnings per share and valuation.

Galmed Pharmaceuticals has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

11.6% of Trevena shares are held by institutional investors. Comparatively, 31.5% of Galmed Pharmaceuticals shares are held by institutional investors. 5.2% of Trevena shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Trevena and Galmed Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current recommendations and price targets for Trevena and Galmed Pharmaceuticals, as provided by MarketBeat.com.

Trevena currently has a consensus price target of $5.00, suggesting a potential upside of 168.82%. Galmed Pharmaceuticals has a consensus price target of $18.1429, suggesting a potential upside of 490.97%. Given Galmed Pharmaceuticals' higher probable upside, analysts clearly believe Galmed Pharmaceuticals is more favorable than Trevena.

Summary

Trevena beats Galmed Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

CymaBay Therapeutics (NASDAQ:CBAY) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.

Insider and Institutional Ownership

84.3% of CymaBay Therapeutics shares are held by institutional investors. Comparatively, 31.5% of Galmed Pharmaceuticals shares are held by institutional investors. 4.0% of CymaBay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares CymaBay Therapeutics and Galmed Pharmaceuticals' top-line revenue, earnings per share and valuation.

Galmed Pharmaceuticals has higher revenue and earnings than CymaBay Therapeutics. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than CymaBay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for CymaBay Therapeutics and Galmed Pharmaceuticals, as provided by MarketBeat.com.

CymaBay Therapeutics currently has a consensus target price of $11.7692, indicating a potential upside of 172.44%. Galmed Pharmaceuticals has a consensus target price of $18.1429, indicating a potential upside of 490.97%. Given Galmed Pharmaceuticals' higher probable upside, analysts plainly believe Galmed Pharmaceuticals is more favorable than CymaBay Therapeutics.

Volatility & Risk

CymaBay Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 2.3, suggesting that its share price is 130% more volatile than the S&P 500.

Profitability

This table compares CymaBay Therapeutics and Galmed Pharmaceuticals' net margins, return on equity and return on assets.

Summary

CymaBay Therapeutics beats Galmed Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Galmed Pharmaceuticals (NASDAQ:GLMD) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Valuation and Earnings

This table compares Galmed Pharmaceuticals and Arbutus Biopharma's gross revenue, earnings per share and valuation.

Galmed Pharmaceuticals has higher earnings, but lower revenue than Arbutus Biopharma. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

31.5% of Galmed Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.4% of Arbutus Biopharma shares are owned by institutional investors. 6.7% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Galmed Pharmaceuticals and Arbutus Biopharma's net margins, return on equity and return on assets.

Volatility and Risk

Galmed Pharmaceuticals has a beta of 2.3, indicating that its share price is 130% more volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 3.15, indicating that its share price is 215% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Galmed Pharmaceuticals and Arbutus Biopharma, as provided by MarketBeat.

Galmed Pharmaceuticals currently has a consensus target price of $18.1429, indicating a potential upside of 490.97%. Arbutus Biopharma has a consensus target price of $6.50, indicating a potential upside of 111.73%. Given Galmed Pharmaceuticals' higher possible upside, research analysts clearly believe Galmed Pharmaceuticals is more favorable than Arbutus Biopharma.

Summary

Galmed Pharmaceuticals beats Arbutus Biopharma on 7 of the 12 factors compared between the two stocks.